Infectious Disease Molecular Diagnostics Market Size & Forecast, 2033

Table Of Content

Executive Summary

Research Scope & Segmentation

Research Objectives
Limitations & Assumptions
Market Scope & Segmentation
Currency & Pricing Considered

Market Opportunity Assessment

Emerging Regions / Countries
Emerging Companies
Emerging Applications / End Use

Market Trends

Drivers
Market Warning Factors
Latest Macro Economic Indicators
Geopolitical Impact
Technology Factors

Market Assessment

Porters Five Forces Analysis
Value Chain Analysis

Regulatory Framework

North America
Europe
APAC
Middle East and Africa
LATAM

ESG Trends

Global Infectious Disease Molecular Diagnostics Market Size Analysis

Global Infectious Disease Molecular Diagnostics Market Introduction
By Product
1. Introduction
  1. Product By Value
2. Instruments
  1. By Value
3. Reagents
  1. By Value
4. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Respiratory Diseases
  1. By Value
3. Tuberculosis
  1. By Value
4. Meningitis
  1. By Value
5. Gastrointestinal Tract Infections
  1. By Value
6. HPV
  1. By Value
7. Sexually Transmitted Infections
  1. By Value
8. Sepsis
  1. By Value
9. Drug Resistance Disease
  1. By Value
10. Other Infectious Diseases
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase chain reaction (PCR)
  1. By Value
3. In Situ Hybridization
  1. By Value
4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
5. Chips and Microarrays
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Sequencing
  1. By Value
8. Transcription Mediated Amplification
  1. By Value
9. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value

North America Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Instruments
  1. By Value
3. Reagents
  1. By Value
4. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Respiratory Diseases
  1. By Value
3. Tuberculosis
  1. By Value
4. Meningitis
  1. By Value
5. Gastrointestinal Tract Infections
  1. By Value
6. HPV
  1. By Value
7. Sexually Transmitted Infections
  1. By Value
8. Sepsis
  1. By Value
9. Drug Resistance Disease
  1. By Value
10. Other Infectious Diseases
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase chain reaction (PCR)
  1. By Value
3. In Situ Hybridization
  1. By Value
4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
5. Chips and Microarrays
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Sequencing
  1. By Value
8. Transcription Mediated Amplification
  1. By Value
9. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
U.S.
1. By Product
  1. Introduction
    1. Product By Value
  2. Instruments
    1. By Value
  3. Reagents
    1. By Value
  4. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Respiratory Diseases
    1. By Value
  3. Tuberculosis
    1. By Value
  4. Meningitis
    1. By Value
  5. Gastrointestinal Tract Infections
    1. By Value
  6. HPV
    1. By Value
  7. Sexually Transmitted Infections
    1. By Value
  8. Sepsis
    1. By Value
  9. Drug Resistance Disease
    1. By Value
  10. Other Infectious Diseases
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase chain reaction (PCR)
    1. By Value
  3. In Situ Hybridization
    1. By Value
  4. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  5. Chips and Microarrays
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Sequencing
    1. By Value
  8. Transcription Mediated Amplification
    1. By Value
  9. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
Canada

Europe Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Instruments
  1. By Value
3. Reagents
  1. By Value
4. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Respiratory Diseases
  1. By Value
3. Tuberculosis
  1. By Value
4. Meningitis
  1. By Value
5. Gastrointestinal Tract Infections
  1. By Value
6. HPV
  1. By Value
7. Sexually Transmitted Infections
  1. By Value
8. Sepsis
  1. By Value
9. Drug Resistance Disease
  1. By Value
10. Other Infectious Diseases
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase chain reaction (PCR)
  1. By Value
3. In Situ Hybridization
  1. By Value
4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
5. Chips and Microarrays
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Sequencing
  1. By Value
8. Transcription Mediated Amplification
  1. By Value
9. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
U.K.
1. By Product
  1. Introduction
    1. Product By Value
  2. Instruments
    1. By Value
  3. Reagents
    1. By Value
  4. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Respiratory Diseases
    1. By Value
  3. Tuberculosis
    1. By Value
  4. Meningitis
    1. By Value
  5. Gastrointestinal Tract Infections
    1. By Value
  6. HPV
    1. By Value
  7. Sexually Transmitted Infections
    1. By Value
  8. Sepsis
    1. By Value
  9. Drug Resistance Disease
    1. By Value
  10. Other Infectious Diseases
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase chain reaction (PCR)
    1. By Value
  3. In Situ Hybridization
    1. By Value
  4. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  5. Chips and Microarrays
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Sequencing
    1. By Value
  8. Transcription Mediated Amplification
    1. By Value
  9. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
Germany
France
Spain
Italy
Russia
Nordic
Benelux
Rest of Europe

APAC Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Instruments
  1. By Value
3. Reagents
  1. By Value
4. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Respiratory Diseases
  1. By Value
3. Tuberculosis
  1. By Value
4. Meningitis
  1. By Value
5. Gastrointestinal Tract Infections
  1. By Value
6. HPV
  1. By Value
7. Sexually Transmitted Infections
  1. By Value
8. Sepsis
  1. By Value
9. Drug Resistance Disease
  1. By Value
10. Other Infectious Diseases
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase chain reaction (PCR)
  1. By Value
3. In Situ Hybridization
  1. By Value
4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
5. Chips and Microarrays
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Sequencing
  1. By Value
8. Transcription Mediated Amplification
  1. By Value
9. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
China
1. By Product
  1. Introduction
    1. Product By Value
  2. Instruments
    1. By Value
  3. Reagents
    1. By Value
  4. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Respiratory Diseases
    1. By Value
  3. Tuberculosis
    1. By Value
  4. Meningitis
    1. By Value
  5. Gastrointestinal Tract Infections
    1. By Value
  6. HPV
    1. By Value
  7. Sexually Transmitted Infections
    1. By Value
  8. Sepsis
    1. By Value
  9. Drug Resistance Disease
    1. By Value
  10. Other Infectious Diseases
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase chain reaction (PCR)
    1. By Value
  3. In Situ Hybridization
    1. By Value
  4. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  5. Chips and Microarrays
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Sequencing
    1. By Value
  8. Transcription Mediated Amplification
    1. By Value
  9. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
Korea
Japan
India
Australia
Singapore
Taiwan
South East Asia
Rest of Asia-Pacific

Middle East and Africa Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Instruments
  1. By Value
3. Reagents
  1. By Value
4. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Respiratory Diseases
  1. By Value
3. Tuberculosis
  1. By Value
4. Meningitis
  1. By Value
5. Gastrointestinal Tract Infections
  1. By Value
6. HPV
  1. By Value
7. Sexually Transmitted Infections
  1. By Value
8. Sepsis
  1. By Value
9. Drug Resistance Disease
  1. By Value
10. Other Infectious Diseases
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase chain reaction (PCR)
  1. By Value
3. In Situ Hybridization
  1. By Value
4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
5. Chips and Microarrays
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Sequencing
  1. By Value
8. Transcription Mediated Amplification
  1. By Value
9. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
UAE
1. By Product
  1. Introduction
    1. Product By Value
  2. Instruments
    1. By Value
  3. Reagents
    1. By Value
  4. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Respiratory Diseases
    1. By Value
  3. Tuberculosis
    1. By Value
  4. Meningitis
    1. By Value
  5. Gastrointestinal Tract Infections
    1. By Value
  6. HPV
    1. By Value
  7. Sexually Transmitted Infections
    1. By Value
  8. Sepsis
    1. By Value
  9. Drug Resistance Disease
    1. By Value
  10. Other Infectious Diseases
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase chain reaction (PCR)
    1. By Value
  3. In Situ Hybridization
    1. By Value
  4. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  5. Chips and Microarrays
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Sequencing
    1. By Value
  8. Transcription Mediated Amplification
    1. By Value
  9. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
Turkey
Saudi Arabia
South Africa
Egypt
Nigeria
Rest of MEA

LATAM Market Analysis

Introduction
By Product
1. Introduction
  1. Product By Value
2. Instruments
  1. By Value
3. Reagents
  1. By Value
4. Services
  1. By Value
By Applications
1. Introduction
  1. Applications By Value
2. Respiratory Diseases
  1. By Value
3. Tuberculosis
  1. By Value
4. Meningitis
  1. By Value
5. Gastrointestinal Tract Infections
  1. By Value
6. HPV
  1. By Value
7. Sexually Transmitted Infections
  1. By Value
8. Sepsis
  1. By Value
9. Drug Resistance Disease
  1. By Value
10. Other Infectious Diseases
  1. By Value
By Technology
1. Introduction
  1. Technology By Value
2. Polymerase chain reaction (PCR)
  1. By Value
3. In Situ Hybridization
  1. By Value
4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  1. By Value
5. Chips and Microarrays
  1. By Value
6. Mass Spectrometry
  1. By Value
7. Sequencing
  1. By Value
8. Transcription Mediated Amplification
  1. By Value
9. Others
  1. By Value
By End-User
1. Introduction
  1. End-User By Value
2. Hospitals
  1. By Value
3. Clinics
  1. By Value
4. Diagnostics Laboratories
  1. By Value
5. Research Institutes
  1. By Value
Brazil
1. By Product
  1. Introduction
    1. Product By Value
  2. Instruments
    1. By Value
  3. Reagents
    1. By Value
  4. Services
    1. By Value
2. By Applications
  1. Introduction
    1. Applications By Value
  2. Respiratory Diseases
    1. By Value
  3. Tuberculosis
    1. By Value
  4. Meningitis
    1. By Value
  5. Gastrointestinal Tract Infections
    1. By Value
  6. HPV
    1. By Value
  7. Sexually Transmitted Infections
    1. By Value
  8. Sepsis
    1. By Value
  9. Drug Resistance Disease
    1. By Value
  10. Other Infectious Diseases
    1. By Value
3. By Technology
  1. Introduction
    1. Technology By Value
  2. Polymerase chain reaction (PCR)
    1. By Value
  3. In Situ Hybridization
    1. By Value
  4. Isothermal Nucleic Acid Amplification Technology (INAAT)
    1. By Value
  5. Chips and Microarrays
    1. By Value
  6. Mass Spectrometry
    1. By Value
  7. Sequencing
    1. By Value
  8. Transcription Mediated Amplification
    1. By Value
  9. Others
    1. By Value
4. By End-User
  1. Introduction
    1. End-User By Value
  2. Hospitals
    1. By Value
  3. Clinics
    1. By Value
  4. Diagnostics Laboratories
    1. By Value
  5. Research Institutes
    1. By Value
Mexico
Argentina
Chile
Colombia
Rest of LATAM

Competitive Landscape

Infectious Disease Molecular Diagnostics Market Share By Players
M&A Agreements & Collaboration Analysis

Market Players Assessment

Abbott
1. Overview
2. Business Information
3. Revenue
4. ASP
5. SWOT Analysis
6. Recent Developments
Becton, Dickinson and Company
biome Rieux SA
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Danaher Corporation
Hologic, Inc. (Gen-Probe)
Illumina, Inc.
Grifols S.A.
Qiagen
F. Hoffmann-La Roche Ltd
Siemens Healthiness AG
Sysmex Corporation

Research Methodology

Research Data
1. Secondary Data
  1. Major secondary sources
  2. Key data from secondary sources
2. Primary Data
  1. Key data from primary sources
  2. Breakdown of primaries
3. Secondary And Primary Research
  1. Key industry insights
Market Size Estimation
1. Bottom-Up Approach
2. Top-Down Approach
3. Market Projection
Research Assumptions
1. Assumptions
Limitations
Risk Assessment